Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)

EU orphan designation number: EU/3/06/405   
Active ingredient: Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
Indication: Treatment of renal cell carcinoma
Sponsor: MOLOGEN AG
Fabeckstraße 30, D-14195 Berlin, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/10/2006 Centralised Orphan - Designation EMEA/OD/021/06 (2006)5152 of 23/10/2006